Angiosarcoma Project
Patient-partnered research approach
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1412 results
Treatment with CAR-NK Cells in Patients with Relapsed or Refractory CD19-positive Lymphoid Tumours
Preliminary results of use of CAR-transduced natural killer cells
EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab
Ruxience is a biosimilar, highly similar to the reference product MabThera, which was authorised in the EU in 1998
EMA Recommends Extension of Indications for Venetoclax
CT Screening Reduces Lung Cancer Mortality
The results from the NELSON study
Adolescent Obesity and Midlife Cancer Risk
Findings from a population-based cohort study
Withdrawal of Application to Change the EU Marketing Authorisation for Pembrolizumab
New use was intended in the treatment of oesophageal cancer
EMA Recommends Granting a Marketing Authorisation for Darolutamide
It is recommended for the treatment of non-metastatic castration resistant prostate cancer at high risk of developing metastatic disease
PIK3CA-mutated Metastatic Breast Cancer
An analysis from SAFIR02 trial results in better understanding of the characteristics of the MBC population harbouring PIK3CA mutations
EMA Suspends Ingenol Mebutate as a Precaution While Review of Skin Cancer Risk Continues
Higher incidence of skin malignancy with ingenol mebutate than with imiquimod
Cancer Related to Infections
An analysis of GLOBOCAN 2018 database points to a need for resources directed towards cancer prevention programmes that target infection
FDA Grants Accelerated Approval to Tazemetostat
It is indicated for metastatic or locally advanced epithelioid sarcoma